Cargando…

A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis

OBJECTIVE: Macrophages mediate inflammation, angiogenesis, and tissue destruction in giant cell arteritis (GCA). Serum levels of the macrophage‐associated protein YKL‐40 (chitinase 3–like protein 1), previously linked to angiogenesis and tissue remodeling, remain elevated in GCA despite glucocortico...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Sleen, Yannick, Jiemy, William F., Pringle, Sarah, van der Geest, Kornelis S. M., Abdulahad, Wayel H., Sandovici, Maria, Brouwer, Elisabeth, Heeringa, Peter, Boots, Annemieke M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298326/ https://www.ncbi.nlm.nih.gov/pubmed/34105308 http://dx.doi.org/10.1002/art.41887

Ejemplares similares

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with tissue destruction and intimal hyperplasia in giant cell arteritis
por: Jiemy, William F, et al.
Publicado: (2020)

Involvement of Monocyte Subsets in the Immunopathology of Giant Cell Arteritis
por: van Sleen, Yannick, et al.
Publicado: (2017)

Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
por: Esen, Idil, et al.
Publicado: (2023)

Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment
por: Esen, Idil, et al.
Publicado: (2021)

Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?
por: van der Geest, Kornelis S. M., et al.
Publicado: (2018)

Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis
por: van Sleen, Yannick, et al.
Publicado: (2019)

Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2019)

Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD8(+) T cells in giant cell arteritis
por: Reitsema, Rosanne D, et al.
Publicado: (2022)

Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2023)

Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica
por: Reitsema, Rosanne D., et al.
Publicado: (2022)

External validation of the 2022 ACR/EULAR classification criteria in patients with suspected giant cell arteritis in a Dutch fast-track clinic
por: van Nieuwland, Marieke, et al.
Publicado: (2023)

Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA
por: Hid Cadena, Rebeca, et al.
Publicado: (2019)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica
por: van der Geest, Kornelis S. M., et al.
Publicado: (2022)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
por: van Sleen, Yannick, et al.
Publicado: (2022)

Performance of the 2022 ACR/EULAR giant cell arteritis classification criteria for diagnosis in patients with suspected giant cell arteritis in routine clinical care
por: Molina-Collada, Juan, et al.
Publicado: (2023)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis
por: Fernández-Fernández, Elisa, et al.
Publicado: (2022)

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
por: Mekinian, Arsène, et al.
Publicado: (2023)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Safe use of tocilizumab in pregnant women with Takayasu arteritis: three case studies
por: Konagai, Nao, et al.
Publicado: (2023)

Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis
por: Jud, Philipp, et al.
Publicado: (2023)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
por: Adriawan, Ignatius Ryan, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
por: Sanchez-Alvarez, Catalina, et al.
Publicado: (2023)

Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
por: Mensch, Noemi, et al.
Publicado: (2023)

Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis
por: Esen, Idil, et al.
Publicado: (2021)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Association between infection and the onset of giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis
por: Pacoureau, Lucas, et al.
Publicado: (2023)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f1d6255vbuo5l3vaseh27pmojg